G Drusano

Summary

Publications

  1. pmc Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation
    Thomas P Lodise
    Albany College, Albany, New York, USA
    Antimicrob Agents Chemother 48:4718-24. 2004
  2. ncbi request reprint Fluoroquinolone Pharmacodynamics: Prospective Determination of Relationships Between Exposure and Outcome
    G L Drusano
    a Division of Clinical Pharmacology, Departments of Medicine and Pharmacology A 142, Albany Medical College, 47 New Scotland Avenue, Albany NY 12208, USA Tel Fax e mail
    J Chemother 12:21-26. 2000
  3. ncbi request reprint Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia
    George L Drusano
    Ordway Research Institute, Albany, New York 12208, USA
    J Infect Dis 189:1590-7. 2004
  4. ncbi request reprint Prevention of resistance: a goal for dose selection for antimicrobial agents
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College and New York State Department of Health, Albany, NY 12208, USA
    Clin Infect Dis 36:S42-50. 2003
  5. pmc Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 46:913-6. 2002
  6. pmc Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 46:586-9. 2002
  7. pmc Pharmacodynamics of abacavir in an in vitro hollow-fiber model system
    G L Drusano
    Division of Clinical Pharmacology, Department of Medicine, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 46:464-70. 2002
  8. ncbi request reprint Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin
    G Drusano
    Department of Medicine, Albany Medical College, NY 12208, USA
    Clin Microbiol Infect 7:24-9. 2001
  9. pmc Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Initiative, Albany Medical College, Albany, New York, USA
    Antimicrob Agents Chemother 45:2115-8. 2001
  10. ncbi request reprint Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College, Albany, NY 12208, USA
    J Infect Dis 183:1126-9. 2001

Detail Information

Publications74

  1. pmc Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation
    Thomas P Lodise
    Albany College, Albany, New York, USA
    Antimicrob Agents Chemother 48:4718-24. 2004
    ..This study indicates that piperacillin-tazobactam should have utility for empirical therapy of hospital-onset infections...
  2. ncbi request reprint Fluoroquinolone Pharmacodynamics: Prospective Determination of Relationships Between Exposure and Outcome
    G L Drusano
    a Division of Clinical Pharmacology, Departments of Medicine and Pharmacology A 142, Albany Medical College, 47 New Scotland Avenue, Albany NY 12208, USA Tel Fax e mail
    J Chemother 12:21-26. 2000
    ..Such relationships will allow rational drug therapy, which may result in maximally efficacious and minimally toxic clinical outcomes for patients and may allow design of regimens to minimize the emergence of drug-resistant pathogens...
  3. ncbi request reprint Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia
    George L Drusano
    Ordway Research Institute, Albany, New York 12208, USA
    J Infect Dis 189:1590-7. 2004
    ..001). Achieving the breakpoint made the patient 4 times more likely to achieve eradication. The effect was greatest in patients > or =67 years old...
  4. ncbi request reprint Prevention of resistance: a goal for dose selection for antimicrobial agents
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College and New York State Department of Health, Albany, NY 12208, USA
    Clin Infect Dis 36:S42-50. 2003
    ..We can do better with our choices of dose, schedule, and combinations of agents. We will need to lower the probability of resistance and maintain the utility of the drugs currently in our therapeutic armamentarium...
  5. pmc Rational dose selection for a nonnucleoside reverse transcriptase inhibitor through use of population pharmacokinetic modeling and Monte Carlo simulation
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 46:913-6. 2002
    ..This prediction was shown to be correct in a randomized, double-blind trial with 1 week of monotherapy with GW 420867X...
  6. pmc Levofloxacin penetration into epithelial lining fluid as determined by population pharmacokinetic modeling and monte carlo simulation
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 46:586-9. 2002
    ..This analysis did not deal with inflammation, as it was performed in volunteers. The influence of lung pathology on penetration needs to be examined...
  7. pmc Pharmacodynamics of abacavir in an in vitro hollow-fiber model system
    G L Drusano
    Division of Clinical Pharmacology, Department of Medicine, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 46:464-70. 2002
    ..These in vitro data also suggest that this drug may be able to be administered to patients on a once-daily basis at a dose of 600 mg...
  8. ncbi request reprint Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin
    G Drusano
    Department of Medicine, Albany Medical College, NY 12208, USA
    Clin Microbiol Infect 7:24-9. 2001
    ..These properties of telithromycin, combined with its good tolerability and low propensity for drug interactions, provide the basis for potent and reliable treatment of RTIs with a convenient, once-daily regimen...
  9. pmc Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Initiative, Albany Medical College, Albany, New York, USA
    Antimicrob Agents Chemother 45:2115-8. 2001
    ..This indicates that AUC is the linked variable and that the anti-influenza effect of RWJ-270201 is independent of schedule. We conclude that once-daily dosing of RWJ-270201 should be evaluated in clinical trials of influenza therapy...
  10. ncbi request reprint Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable
    G L Drusano
    Division of Clinical Pharmacology, Clinical Research Institute, Albany Medical College, Albany, NY 12208, USA
    J Infect Dis 183:1126-9. 2001
    ....
  11. ncbi request reprint Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables
    G L Drusano
    Albany Medical College, New York 12208, USA
    J Infect Dis 178:360-7. 1998
    ..The goal of therapy should be to decrease the HIV-1 RNA load to a less-than-detectable level...
  12. pmc Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir
    G L Drusano
    Department of Medicine, Albany Medical College, New York 12208, USA
    Antimicrob Agents Chemother 42:358-61. 1998
    ....
  13. pmc Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro
    G L Drusano
    Departments of Medicine and Pharmacology Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 42:2153-9. 1998
    ..These data, with favorable findings from phase I/II trials for each drug alone, suggest that the combination of 1592U89 plus 141W94 should be further evaluated in clinical trials...
  14. pmc Use of drug effect interaction modeling with Monte Carlo simulation to examine the impact of dosing interval on the projected antiviral activity of the combination of abacavir and amprenavir
    G L Drusano
    Division of Clinical Pharmacology, Department of Medicine, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 44:1655-9. 2000
    ..This approach may be helpful in the preclinical evaluation of multidrug anti-infective regimens...
  15. pmc A population pharmacokinetic analysis of the penetration of the prostate by levofloxacin
    G L Drusano
    Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 44:2046-51. 2000
    ..14 with a 95% confidence interval of 0.20 to 19.6. Over 70% of the population had a penetration ratio in excess of 1.0. Levofloxacin adequately penetrates a noninflamed prostate and should be evaluated for the therapy of prostatitis...
  16. pmc Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint
    G L Drusano
    Division of Clinical Pharmacology, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 45:13-22. 2001
    ..aureus), 1 log killing (enterococci), or 90% E(max) AUC/MIC targets. This same approach may also be used to set preliminary in vitro MIC breakpoints...
  17. ncbi request reprint Fluoroquinolone pharmacodynamics: prospective determination of relationships between exposure and outcome
    G L Drusano
    Department of Medicine, Albany Medical College, NY 12208, USA
    J Chemother 12:21-6. 2000
    ..Such relationships will allow rational drug therapy, which may result in maximally efficacious and minimally toxic clinical outcomes for patients and may allow design of regimens to minimize the emergence of drug-resistant pathogens...
  18. doi request reprint Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults
    Frances H Priddy
    Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA
    Clin Infect Dis 46:1769-81. 2008
    ....
  19. pmc Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:2329-36. 2007
    ....
  20. pmc Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects
    Thomas P Lodise
    Ordway Research Institute, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:2378-87. 2007
    ..v. q12h, for patients who had a creatinine clearance rate of < or =50 ml/min, was identified as the most appropriate treatment regimen for patients who require renal dose adjustment for mild to moderate renal impairment...
  21. ncbi request reprint Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Clin Infect Dis 44:357-63. 2007
    ..This study evaluates the clinical implications of extended infusion of piperacillin-tazobactam therapy for critically ill patients with P. aeruginosa infection...
  22. pmc The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: a new paradigm for optimizing pharmacodynamics to counterselect resistance
    Vincent H Tam
    Emerging Infections and Host Defense Laboratory, Ordway Research Institute, Albany, NY, USA
    Antimicrob Agents Chemother 51:744-7. 2007
    ..Different targets for the area under the concentration-time curve over 24 h/MIC ratio were required for different bacteria...
  23. pmc Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model
    L Mark Kao
    Johnson and Johnson Pharmaceutical Research and Development, LLC, 1000 Route 202 South, Raritan, NJ 08869, USA
    Antimicrob Agents Chemother 50:3535-42. 2006
    ..These data demonstrate that a humanized dosing regimen of levofloxacin was effective in preventing morbidity and mortality from inhalational anthrax in rhesus monkeys and did not select for resistance...
  24. ncbi request reprint Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole
    Kelly A Sprandel
    College of Pharmacy, University of Illinois, Chicago, IL 60612, USA
    Diagn Microbiol Infect Dis 55:303-9. 2006
    ..Based on this model, attainment of the target pharmacodynamic parameter (AUC/MIC ratio >or=70) against B. fragilis isolates is >99% when MICs are <2 mg L(-1), irrespective of the dosing interval of 24 h...
  25. pmc Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae
    Nelson L Jumbe
    Ordway Research Institute, 150 New Scotland Avenue, Albany, New York 12208, USA
    Antimicrob Agents Chemother 50:310-7. 2006
    ..To preserve the susceptibility of Streptococcus pneumoniae to newer members of the class of quinolones, use of ciprofloxacin for community-acquired respiratory infections should be minimized...
  26. pmc Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing
    William W Hope
    Pediatric Oncology Branch, NCI NIH, CRC Room 1 5750, Bethesda, MD 20892 1100, USA
    Antimicrob Agents Chemother 51:3714-9. 2007
    ....
  27. doi request reprint Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection
    Gerd Fatkenheuer
    Universitätsklinik Köln, Cologne, Germany
    N Engl J Med 359:1442-55. 2008
    ....
  28. pmc Maraviroc for previously treated patients with R5 HIV-1 infection
    Roy M Gulick
    Weill Cornell Medical College, New York, NY 10065, USA
    N Engl J Med 359:1429-41. 2008
    ..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
  29. pmc Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation
    Thomas P Lodise
    Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208 3492, USA
    Antimicrob Agents Chemother 52:2300-4. 2008
    ..The median AUC(ELF)/free AUC(plasma) penetration ratio was 0.73, and the 25th and 75th percentile value ratios were 0.43 and 1.24, respectively. In uninfected lung tissue, the median AUC(ELF) is approximately 75% of the free AUC(plasma)...
  30. doi request reprint Use of pharmacodynamic endpoints for the evaluation of levofloxacin for the treatment of acute maxillary sinusitis
    Paul G Ambrose
    ICPD Ordway Research Institute, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 61:13-20. 2008
    ..1 (n = 14, %CV = 27). Plasma AUC/MIC ratios ranged from 33.9 to 1696 for isolated pathogens. In this pilot SSAS study, levofloxacin rapidly eradicated isolated pathogens from the maxillary sinus...
  31. ncbi request reprint Prevalence of drug-resistant and nonsubtype B HIV strains in antiretroviral-naïve, HIV-infected individuals in New York State
    Monica M Parker
    Wadsworth Center, New York State Department of Health, Albany, New York, USA
    AIDS Patient Care STDS 21:644-52. 2007
    ..Furthermore, a diverse set of nonsubtype B strains were identified and evidence suggests that nonsubtype B strains, including those carrying drug-resistance mutations, are being transmitted in New York State...
  32. pmc Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:4351-5. 2007
    ..Sensitivity analyses suggest that the probability of PK-PD target attainment in adults and children is not affected by increases in MICs for strains of B. anthracis to levels as high as 0.5 mg/liter...
  33. pmc In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae
    Arnold Louie
    Emerging Infection and Host Defense Theme, Ordway Research Institute, 150 New Scotland Ave, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:3988-4000. 2007
    ..Ciprofloxacin in combination with reserpine prevented the emergence of resistance in Spn-058 but not in Spn-RC2, the EP-overexpressing strain...
  34. pmc Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation
    Christopher M Rubino
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:4085-9. 2007
    ..15 (0.561 and 5.23), respectively. Simulation results predict that tissue penetration varies considerably and likely explain unexpected clinical outcomes for those patients infected with strains at margins of the MIC distribution...
  35. ncbi request reprint Explaining the poor bacteriologic eradication rate of single-dose ceftriaxone in group a streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling
    Jeffrey L Blumer
    Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
    Pediatrics 116:927-32. 2005
    ....
  36. pmc Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance
    Tawanda Gumbo
    Emerging Infections and Host Defense Theme, Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
    Antimicrob Agents Chemother 49:3178-81. 2005
    ..One of the explanations for why early bactericidal activity fails to predict sterilization may be the emergence of a resistant subpopulation, which only becomes >/=1% at the end of the early bactericidal activity studies...
  37. ncbi request reprint Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir
    Mohammad M Hossain
    Department of Internal Medicine, Division of Infectious Diseases, North Texas Veterans Health Care Systems, Dallas, TX, USA
    Antiviral Res 55:41-52. 2002
    ..These findings provide further rationale for the clinical testing of MMF in combination with ABC, DDI, and TFV...
  38. ncbi request reprint Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa
    Vincent H Tam
    Emerging Infections and Host Defense Theme, Ordway Research Institute, Albany, NY 12208, USA
    J Infect Dis 192:420-8. 2005
    ....
  39. ncbi request reprint Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
    Johan W Mouton
    Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Weg door Jonkerbos 100, 6532 SZ Nijmegen, The Netherlands
    J Antimicrob Chemother 55:601-7. 2005
    ..This paper describes in a uniform manner the use of PK/PD expressions for antimicrobial agents, and their units...
  40. ncbi request reprint Pharmacodynamics and clinical use of anti-HIV drugs
    Sandra L Preston
    Clinical Research Institute, Division of Clinical Pharmacology, Albany Medical College, 47 New Scotland Avenue, mc142, Albany, NY 12208, USA
    Infect Dis Clin North Am 17:651-74. 2003
    ..TDM, in conjunction with an assessment of the patient's viral resistance in the form of an IQ, needs to be examined and validated in large clinical trials...
  41. ncbi request reprint Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa
    Vincent H Tam
    Division of Clinical Pharmacology, Albany Medical College, and New York State Department of Health, USA
    Pharmacotherapy 23:291-5. 2003
    ..To derive steady-state pharmacokinetic profiles of cefepime against Pseudomonas aeruginosa...
  42. pmc Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function
    Vincent H Tam
    Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, Wayne State University, Detroit, Michigan 48201, USA
    Antimicrob Agents Chemother 47:1853-61. 2003
    ..Current dosing recommendations may be suboptimal for monotherapy of infections due to less susceptible pathogens (e.g., those for which MICs are > or = 4 mg/liter), particularly when CL(CR) exceeds 120 ml/min...
  43. pmc Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy
    Nelson Jumbe
    Ordway Research Institute, Albany, New York 12208, USA
    J Clin Invest 112:275-85. 2003
    ..The methods developed in this study provide insight regarding how mathematical models can be used to identify rational dosing regimens that suppress the amplification of the resistant mutant population...
  44. ncbi request reprint Surface response modeling to examine the combination of amphotericin B deoxycholate and 5-fluorocytosine for treatment of invasive candidiasis
    William W Hope
    Department of Medicine, University of Manchester, Manchester, UK
    J Infect Dis 192:673-80. 2005
    ..Our methods provide a way in which some of the complex issues surrounding antifungal combination treatment can be addressed...
  45. pmc Optimization of the dosage of flucytosine in combination with amphotericin B for disseminated candidiasis: a pharmacodynamic rationale for reduced dosing
    William W Hope
    Department of Medicine, The University of Manchester, 1 800 Stopford Building, Oxford Road, Manchester, UK
    Antimicrob Agents Chemother 51:3760-2. 2007
    ..Here, we bridge the results of an experimental pharmacodynamic study to humans and demonstrate that a 5FC dosage of 25 mg/kg of body weight/day in four divided doses in combination with amphotericin B produces near-maximal effect...
  46. ncbi request reprint Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague
    Henry S Heine
    US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, 21702, USA
    J Infect Dis 196:782-7. 2007
    ..Intentional release of Yersinia pestis will likely be propagated by aerosol exposure. We explored the effects of neutropenia on the outcome of doxycycline and gentamicin therapy...
  47. pmc Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial
    Samir G Sakka
    Department of Anesthesiology and Intensive Care Medicine, Friedrich Schiller University of Jena, Jena, Germany
    Antimicrob Agents Chemother 51:3304-10. 2007
    ..Larger clinical trials are warranted for evaluation of continuous infusions at a reduced dose of imipenem for critically ill patients...
  48. pmc Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin
    Tawanda Gumbo
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:3781-8. 2007
    ..tuberculosis, (ii) the achievement of a free C(max)/MIC of >175 that can be tolerated by patients, and (iii) a long postantibiotic effect duration...
  49. ncbi request reprint Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling
    Vincent H Tam
    Division of Clinical Pharmacology, Ordway Research Institute, Albany, NY 12208, USA
    Pharmacotherapy 23:1545-9. 2003
    ..To compare the two-stage method, a widely used analytical method in pharmacokinetic studies, with nonparametric population modeling by using the same data set for determining the oral bioavailability of ribavirin...
  50. ncbi request reprint Predicting efficacy of antiinfectives with pharmacodynamics and Monte Carlo simulation
    John S Bradley
    Division of Infectious Diseases, Children s Hospital, San Diego, CA, USA
    Pediatr Infect Dis J 22:982-92; quiz 993-5. 2003
  51. pmc In vitro-in vivo model for evaluating the antiviral activity of amprenavir in combination with ritonavir administered at 600 and 100 milligrams, respectively, every 12 hours
    Sandra L Preston
    Division of Clinical Pharmacology, Clinical Research Initiative, Albany Medical College, Albany, New York 12208, USA
    Antimicrob Agents Chemother 47:3393-9. 2003
    ..05 micro M. Even at 0.12 microM, target attainment likelihood exceeds 50%, making this an option for patients with extensive exposure to protease inhibitors when this treatment is used with additional active antiretroviral agents...
  52. pmc The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates
    William W Hope
    Immunocompromised Host Section, Pediatric Oncology Branch, CRC, Rm 1 5750, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 197:163-71. 2008
    ..The outcome after antifungal therapy is often suboptimal, with few therapeutic options. Limited clinical data suggest that echinocandins may have role to play in the treatment of HCME...
  53. ncbi request reprint Guillain-Barré syndrome associated with immune reconstitution
    Peter J Piliero
    Albany Medical College, Albany, New York 12208, USA
    Clin Infect Dis 36:e111-4. 2003
    ..We hypothesize that GBS may have been due to an aberrant immune response or an adverse drug reaction in association with preexisting peripheral neurologic disease...
  54. doi request reprint Pharmacokinetics-pharmacodynamics of quinolones against Streptococcus pneumoniae in patients with community-acquired pneumonia
    Sujata M Bhavnani
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12206 1072, USA
    Diagn Microbiol Infect Dis 62:99-101. 2008
    ..Such data may be useful to establish prior expectations for the no-treatment effect when conducting noninferiority clinical trials...
  55. ncbi request reprint Pharmacodynamics of cefepime in patients with Gram-negative infections
    Vincent H Tam
    The Anti Infective Research Laboratory, Department of Pharmacy Services, Detroit Receiving Hospital and University Health Center, Wayne State University, MI, USA
    J Antimicrob Chemother 50:425-8. 2002
    ..3 x MIC. Our results support in vitro data that suggest bactericidal activity of beta-lactams is optimized at concentrations approximately 4 x MIC. These results should be validated by large prospective clinical trials...
  56. pmc Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin
    Cornelia B Landersdorfer
    Institute for Biomedical and Pharmaceutical Research, Nürnberg Heroldsberg, Germany
    Antimicrob Agents Chemother 51:3290-7. 2007
    ..Prolonged infusion and continuous infusion are appealing options for the treatment of serious infections caused by sensitive staphylococci...
  57. pmc Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors
    James J McSharry
    Center for Immunology and Microbial Disease and Clinical Research Initiative, Albany Medical College, Albany, New York 12208, USA
    Clin Diagn Lab Immunol 11:21-8. 2004
    ..The assay may be useful for determining the in vivo susceptibilities of other compounds effective against influenza A and B viruses...
  58. ncbi request reprint Infection site concentrations: their therapeutic importance and the macrolide and macrolide-like class of antibiotics
    George L Drusano
    Ordway Research Institute, Albany, New York 12208, USA
    Pharmacotherapy 25:150S-158S. 2005
    ....
  59. ncbi request reprint Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies
    Thomas P Lodise
    Department of Pharmacy Practice, Albany College of Pharmacy, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 54:223-30. 2006
    ..03 and 8 microg/mL for each regimen examined. In CSF, none of the regimens achieved 50-100% T>MIC for>80% of patients for MICs>0.5 mg/L...
  60. ncbi request reprint Pharmacodynamics of an 800-mg dose of telithromycin in patients with community-acquired pneumonia caused by extracellular pathogens
    Thomas P Lodise
    Albany College of Pharmacy, Albany Medical College, Albany, NY 12208, USA
    Diagn Microbiol Infect Dis 52:45-52. 2005
    ..1% for H. influenzae. This study demonstrated a relationship between telithromycin drug exposure and microbiological outcome. Telithromycin is expected to achieve the drug exposure breakpoint for the majority of isolates causing CAP...
  61. ncbi request reprint Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on beta-lactam antibiotics: insights from the Society of Infectious Diseases Pharmacists
    Thomas P Lodise
    Albany College of Pharmacy, Albany, New York 12208, USA
    Pharmacotherapy 26:1320-32. 2006
    ..Moreover, they achieved the targeted fT>MIC with less administration time/day than would be needed for continuous infusion...
  62. pmc Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis
    Tawanda Gumbo
    Division of Infectious Diseases, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 50:3695-700. 2006
    ..This pharmacokinetic-pharmacodynamic picture of anidulafungin persistence in tissues and the resultant persistent fungal decline should be exploited to improve the efficacy of anidulafungin therapy for candidemia...
  63. pmc Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect
    William W Hope
    Pediatric Oncology Branch, NCI NIH, CRC Rm 1 5750, 10 Center Dr, MSC 1100, Bethesda MD 20892 1100, USA
    Antimicrob Agents Chemother 50:3680-8. 2006
    ..The in vivo growth rate was a critical additional determinant of the exposure-response relationship. There was a relationship between the 5FC resistance genotype and the exposure-response relationship...
  64. pmc Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers
    Wolfgang A Krueger
    IBMP Institute for Biomedical and Pharmaceutical Research, Paul Ehrlich Str 19, D 90562 Nürnberg Heroldsberg, Germany
    Antimicrob Agents Chemother 49:1881-9. 2005
    ..We conclude that clinical trials for evaluation of the continuous infusions of meropenem in critically ill patients are warranted...
  65. pmc Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis
    William W Hope
    Pediatric Oncology Branch, NCI NIH, CRC Room 1 5750, 10 Center Dr, MSC 1100, Bethesda, MD 20892 1100, USA
    Antimicrob Agents Chemother 51:285-95. 2007
    ..Neutrophils and the timely initiation of antifungal agents are critical determinants in the treatment of experimental disseminated candidiasis...
  66. ncbi request reprint Sex differences in CYP3A activity using intravenous and oral midazolam
    Maylee Chen
    Ordway Research Institute Drug Development Center, Albany, NY 12206 1066, USA
    Clin Pharmacol Ther 80:531-8. 2006
    ..Our objective is to investigate whether sex differences exist in CYP3A activity as assessed by intravenous (IV) or oral midazolam pharmacokinetic analysis in healthy volunteers...
  67. ncbi request reprint Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore
    Paul G Ambrose
    Institute for Clinical Pharmacodynamics, Ordway Research Institute, Albany, NY 12208, USA
    Clin Infect Dis 44:79-86. 2007
    ..Over the past 15 years, considerable PK-PD data have been derived from infected patients for many classes of antimicrobial agents. These data provide the opportunity to confirm knowledge gained from animal PK-PD infection models...
  68. ncbi request reprint Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth
    Tawanda Gumbo
    Emerging Infections and Host Defenses Section, Ordway Research Institute, Albany, NY, USA
    J Infect Dis 195:194-201. 2007
    ..We examined the veracity of this cornerstone belief...
  69. pmc Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia
    Tawanda Gumbo
    Division of Infectious Diseases, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390 9113, USA
    Antimicrob Agents Chemother 51:968-74. 2007
    ..Once-weekly micafungin therapy is as efficacious as daily therapy in a murine model of disseminated candidiasis...
  70. ncbi request reprint Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy
    William W Hope
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Infect Dis 195:455-66. 2007
    ..Little is known about the pathogenesis of invasive pulmonary aspergillosis and the relationship between the kinetics of diagnostic markers and the outcome of antifungal therapy...
  71. ncbi request reprint Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
    Tawanda Gumbo
    Emerging Infections and Host Defense Section, Ordway Research Institute, Albany, New York 12208, USA
    J Infect Dis 190:1642-51. 2004
    ..To optimize moxifloxacin dose and dose regimen, pharmacodynamic antibiotic-exposure targets associated with maximal microbial kill and complete suppression of drug resistance in M. tuberculosis must be identified...
  72. ncbi request reprint Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
    George L Drusano
    Ordway Research Institute, 150 New Scotland Avenue, Albany, New York 12208, USA
    Nat Rev Microbiol 2:289-300. 2004
  73. pmc Use of population pharmacokinetic modeling and Monte Carlo simulation to describe the pharmacodynamic profile of cefditoren in plasma and epithelial lining fluid
    Thomas P Lodise
    Institute for Biomedical and Pharmaceutical Research, Nürnberg Heroldsberg, Germany
    Antimicrob Agents Chemother 52:1945-51. 2008
    ..06 mg/liter, which includes most S. pneumoniae isolates with intermediate susceptibility to penicillin, when given in the fasting state in both plasma and ELF...
  74. pmc Impact of resistance selection and mutant growth fitness on the relative efficacies of streptomycin and levofloxacin for plague therapy
    Arnold Louie
    Emerging Infections and Host Defense Section, Ordway Research Institute, Albany, NY 12208, USA
    Antimicrob Agents Chemother 51:2661-7. 2007
    ..Thus, the fluoroquinolone antibiotic levofloxacin was superior to streptomycin in our in vitro infection model. The majority of levofloxacin-resistant mutants were less fit than streptomycin-resistant and wild-type Y. pestis...